Galectin-1 Inhibits the Viability, Proliferation, and Th1 Cytokine Production of Nonmalignant T Cells in Patients with Leukemic Cutaneous T-cell Lymphoma

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Mar 3

PMID 22383798

Citations 41

Authors

Filiberto Cedeno-Laurent

Rei Watanabe

Jessica E Teague

Thomas S Kupper

Rachael A Clark

Charles J Dimitroff

Affiliations

Soon will be listed here.

Abstract

Tumor-derived galectin-1 (Gal-1), a β-galactoside-binding S-type lectin, has been shown to encourage T-cell death and promote T cell-mediated tumor immune escape. In this report, we show that patients with leukemic cutaneous T-cell lymphomas, known to have limited complexity of their T-cell repertoires, have a predominant T helper type-2 (Th2) cytokine profile and significantly elevated plasma levels of Gal-1 compared with healthy controls. Circulating clonal malignant T cells were a major source of Gal-1. The conditioned supernatant of cultured malignant T cells induced a β-galactoside-dependent inhibition of normal T-cell proliferation and a Th2 skewing of cytokine production. These data implicate Gal-1 in development of the Th2 phenotype in patients with advanced-stage cutaneous T-cell lymphoma and highlight the Gal-1-Gal-1 ligand axis as a potential therapeutic target for enhancing antitumor immune responses.

Citing Articles

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells.

Herman K, Holyer I, Humphries D, Adamska A, Roper J, Peterson K Int J Mol Sci. 2024; 25(22).

PMID: 39596018 PMC: 11593614. DOI: 10.3390/ijms252211948.

Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth.

Qin L, Xu J, Chen J, Wang S, Zheng R, Cui Z Elife. 2024; 13.

PMID: 39495223 PMC: 11534329. DOI: 10.7554/eLife.92737.

Galectin-1 is associated with hematopoietic cell engraftment in murine MHC-mismatched allotransplantation.

Shaikh A, Gangaplara A, Kone A, Almengo K, Kabore M, Ali M Front Immunol. 2024; 15:1411392.

PMID: 39351218 PMC: 11439684. DOI: 10.3389/fimmu.2024.1411392.

Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.

Srinivas N, Peiffer L, Horny K, Lei K, Buus T, Kubat L Front Oncol. 2024; 14:1408614.

PMID: 39169943 PMC: 11337020. DOI: 10.3389/fonc.2024.1408614.

Knockdown of the Shwachman-Diamond syndrome gene, SBDS, induces galectin-1 expression and impairs cell growth.

Yamaguchi M, Sera Y, Toga-Yamaguchi H, Kanegane H, Iguchi Y, Fujimura K Int J Hematol. 2024; 119(4):383-391.

PMID: 38240987 DOI: 10.1007/s12185-024-03709-z.

References

Cedeno-Laurent F, Barthel S, Opperman M, Lee D, Clark R, Dimitroff C . Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol. 2010; 185(8):4659-72. PMC: 2953643. DOI: 10.4049/jimmunol.1000715. View

Le Q, Shi G, Cao H, Nelson D, Wang Y, Chen E . Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005; 23(35):8932-41. DOI: 10.1200/JCO.2005.02.0206. View

Roberts A, Amano M, Felten C, Galvan M, Sulur G, Pinter-Brown L . Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol. 2003; 16(6):543-51. DOI: 10.1097/01.MP.0000071840.84469.06. View

Cedeno-Laurent F, Opperman M, Barthel S, Kuchroo V, Dimitroff C . Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 2012; 188(7):3127-37. PMC: 3311782. DOI: 10.4049/jimmunol.1103433. View

Wollina U, Graefe T, Feldrappe S, Andre S, Wasano K, Kaltner H . Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J Cancer Res Clin Oncol. 2002; 128(2):103-10. DOI: 10.1007/s00432-001-0304-3. View

Pace K, Hahn H, Pang M, Nguyen J, Baum L . CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol. 2000; 165(5):2331-4. DOI: 10.4049/jimmunol.165.5.2331. View

Cedeno-Laurent F, Opperman M, Barthel S, Hays D, Schatton T, Zhan Q . Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol. 2011; 132(2):410-20. PMC: 3258338. DOI: 10.1038/jid.2011.335. View

Yamanaka K, Clark R, Dowgiert R, Hurwitz D, Shibata M, Rich B . Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res. 2006; 12(2):376-82. DOI: 10.1158/1078-0432.CCR-05-1777. View

Barthel S, Antonopoulos A, Cedeno-Laurent F, Schaffer L, Hernandez G, Patil S . Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J Biol Chem. 2011; 286(24):21717-31. PMC: 3122228. DOI: 10.1074/jbc.M110.194597. View

10.

Miyagaki T, Sugaya M, Fujita H, Ohmatsu H, Kakinuma T, Kadono T . Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol. 2010; 130(9):2304-11. DOI: 10.1038/jid.2010.128. View

11.

Rappl G, Abken H, Muche J, Sterry W, Tilgen W, Andre S . CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia. 2002; 16(5):840-5. DOI: 10.1038/sj.leu.2402438. View

12.

Rubinstein N, Alvarez M, Zwirner N, Toscano M, Ilarregui J, Bravo A . Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004; 5(3):241-51. DOI: 10.1016/s1535-6108(04)00024-8. View

13.

Gandhi M, Moll G, Smith C, Dua U, Lambley E, Ramuz O . Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood. 2007; 110(4):1326-9. PMC: 1939905. DOI: 10.1182/blood-2007-01-066100. View

14.

Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C . The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003; 148(4):709-18. DOI: 10.1046/j.1365-2133.2003.05224.x. View

15.

Juszczynski P, Ouyang J, Monti S, Rodig S, Takeyama K, Abramson J . The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007; 104(32):13134-9. PMC: 1936978. DOI: 10.1073/pnas.0706017104. View

16.

Yawalkar N, Ferenczi K, Jones D, Yamanaka K, Suh K, Sadat S . Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood. 2003; 102(12):4059-66. DOI: 10.1182/blood-2003-04-1044. View

17.

Rodig S, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg D . AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008; 14(11):3338-44. DOI: 10.1158/1078-0432.CCR-07-4709. View

18.

Toscano M, Bianco G, Ilarregui J, Croci D, Correale J, Hernandez J . Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol. 2007; 8(8):825-34. DOI: 10.1038/ni1482. View

19.

Vowels B, Cassin M, Vonderheid E, Rook A . Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol. 1992; 99(1):90-4. DOI: 10.1111/1523-1747.ep12611877. View

20.

Cedeno-Laurent F, Dimitroff C . Galectin-1 research in T cell immunity: past, present and future. Clin Immunol. 2011; 142(2):107-16. PMC: 3266984. DOI: 10.1016/j.clim.2011.09.011. View